1100212-65-4

Basic information

• Product Name: 2-bromo-6-methyl-4-(trifluoromethyl)aniline
• Synonyms: 2-bromo-6-methyl-4-(trifluoromethyl)aniline;Benzenamine, 2-bromo-6-methyl-4-(trifluoromethyl)-
• CAS NO: 1100212-65-4
• Molecular Formula: C₈H₇BrF₃N
• Molecular Weight: 254.0470896
• Mol File: 1100212-65-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-bromo-6-methyl-4-(trifluoromethyl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-6-methyl-4-(trifluoromethyl)aniline(1100212-65-4)
• EPA Substance Registry System: 2-bromo-6-methyl-4-(trifluoromethyl)aniline(1100212-65-4)

Safety Data

• Hazardous Substances Data: 1100212-65-4(Hazardous Substances Data)

Upstream product

• 57946-63-1 4-amino-3-bromobenzotrifluoride 
• 67169-22-6 2-methyl-4-(trifluoromethyl)benzenamine 

Downstream Products

• 1100212-66-5 7-bromo-5-(trifluoromethyl)-1H-indazole 

Relevant articles and documents

5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

AhR MODULATORS

Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: (I) wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.